Get the Stockscreener App
12.12
3.21%
-0.3253
Kalvista Pharmaceuticals Inc stock is traded at $12.12, with a volume of 128.44K.
It is down -3.21% in the last 24 hours and up +26.44% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
See More
Previous Close:
$12.45
Open:
$12.35
24h Volume:
128.44K
Relative Volume:
0.32
Market Cap:
$607.10M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-3.2858
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+0.58%
1M Performance:
+26.44%
6M Performance:
+8.17%
1Y Performance:
-3.52%
1-Day Range:
$12.04
$12.57
1-Week Range:
$11.53
$12.90
52-Week Range:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
12.04 | 607.10M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.00 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.15 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.42 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.21 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.40 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Jefferies cuts Kalvista stock price target to $31 from $33 By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Advances Sebetralstat for HAE - TipRanks
KalVista Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31Earnings Summary - TradingView
KALVISTA PHARMACEUTICALS Earnings Results: $KALV Reports Quarterly Earnings - Nasdaq
KalVista's Oral HAE Treatment Delivers 76-Minute Relief as FDA Review Nears - StockTitan
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - The Bakersfield Californian
Reviewing KalVista Pharmaceuticals (NASDAQ:KALV) and Hillstream BioPharma (NASDAQ:HILS) - Defense World
KalVista Pharmaceuticals CEO sells $79,827 in stock By Investing.com - Investing.com Australia
KalVista Pharmaceuticals CEO sells $79,827 in stock - Investing.com
KalVista Pharmaceuticals CEO Sells Shares to Cover Tax Obligations - TradingView
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - The Bakersfield Californian
KalVista to Present Commercial Strategy for New HAE Treatment Sebetralstat - StockTitan
Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock - MSN
JMP reiterates Kalvista stock with $19 target, sees market growth - MSN
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Joplin Globe
KalVista Issues 14,000 Share Options to New HiresWhat This Means for KALV Investors - StockTitan
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting - BioSpace
Sebetralstat shows promise in treating HAE attacks By Investing.com - Investing.com Canada
Sebetralstat shows promise in treating HAE attacks - Investing.com India
KalVista stock holds firm with $19 target from JMP - Investing.com India
KalVista stock holds firm with $19 target from JMP By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on Monday - Defense World
Revolutionary Oral HAE Treatment From KalVista Achieves 96% Effectiveness in Minutes - StockTitan
KalVista Pharmaceuticals’ Sebetralstat: A Game-Changer in Oral HAE Treatment with Strong Market Potential - TipRanks
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Buy" from Brokerages - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,394 Shares - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $23.80 Average Price Target from Brokerages - Defense World
KalVista Pharmaceuticals’ chief development officer sells $19,218 in stock - Investing.com India
KalVista Pharmaceuticals CMO Audhya Paul sells $23,987 in stock - Investing.com India
KalVista Pharmaceuticals CMO Audhya Paul sells $23,987 in stock By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals’ chief development officer sells $19,218 in stock By Investing.com - Investing.com UK
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Bakersfield Californian
Can KalVista's March Conference Circuit Signal Major Pipeline Updates? - StockTitan
Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells 3,125 Shares of Stock - MarketBeat
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting - Business Wire
Can This New Oral Drug Transform HAE Treatment? Key Clinical Data Revealed - StockTitan
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 Shares - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 8.7%What's Next? - MarketBeat
KalVista Pharmaceuticals chief medical officer sells $30,700 in stock By Investing.com - Investing.com Canada
KalVista Pharmaceuticals CEO sells $50,142 in stock - Investing.com India
KalVista Pharmaceuticals chief medical officer sells $30,700 in stock - Investing.com India
KalVista Pharmaceuticals chief development officer sells shares for $25,552 - Investing.com India
KalVista Pharmaceuticals CEO sells $50,142 in stock By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals chief development officer sells shares for $25,552 By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - Defense World
Japan grants orphan drug status to HAE treatment - MSN
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):